Tobin Schilke - Feb 15, 2023 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
Feb 15, 2023
Transactions value $
-$69,243
Form type
4
Date filed
2/16/2023, 07:28 PM
Previous filing
Feb 2, 2023
Next filing
Mar 2, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Tax liability -$69.2K -2.09K -3.81% $33.21 52.6K Feb 15, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award (the "RSA") for 5,500 shares. The RSA vested in three equal annual installments from February 15, 2020.